试验对象为先前化疗后仍进展的患者，且胰腺癌通常在诊断时已进展到晚期：约80%的患者肿瘤已转移，导致多数无法手术。Manuel Hidalgo称这是该领域「最重要」的临床资料之一；Wungki Park回顾患者反应时亦表示非常惊异。这一结果将期望值推高，暗示未来治疗成效有可能从「多几个月」推进到「更多年」。
研究下一步重点包括亚群分析（如特定基因突变、转移部位、既往化疗类型）与长期安全性：daraxonrasib可致皮疹与肠胃道副作用，Ben Sasse案例还出现明显面部出血。Mark Goldsmith表示公司正加速监管申报流程；在FDA新设的CNPV快速审查机制下，若符合条件，审查时间可缩短至1至2个月。文章还提及正在进行的新诊断人群试验，以确认早期使用是否带来更高疗效。
Revolution Medicines’ pancreatic cancer drug daraxonrasib was reported to nearly double median overall survival in a late-stage trial: 13.2 months (about 1.1 years) versus 6.7 months (about 0.56 years) with chemotherapy alone. In a field where gains have often been measured in days or weeks, this is a major clinical signal. The article also notes that pancreatic cancer remains highly lethal in the U.S., ranking third after lung and colorectal cancer, with about 53,000 deaths projected in 2026.
The trial enrolled patients whose disease had progressed after prior chemotherapy, and the disease context is severe: around 80% of patients already have metastatic spread at diagnosis, making many non-operable. Manuel Hidalgo called the result one of the most important clinical datasets in pancreatic cancer, and Wungki Park said patient responses were strikingly strong. The finding raises expectations, suggesting future progress might eventually be discussed in years rather than only months.
The next focus is subgroup analysis (mutation status, metastatic pattern, prior regimen) and safety characterization. Daraxonrasib can cause rashes and gastrointestinal effects, and the reported Ben Sasse case included notable facial bleeding. Mark Goldsmith said the company is moving regulatory submissions as fast as possible, and under FDA’s CNPV fast-track pathway review may be as short as 1 to 2 months if applicable. Ongoing trials in newly diagnosed patients are meant to test whether earlier use improves outcomes.